| Schmitz, Norbert |
R-CHOEP-brut, NCT03399513: Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma |
|
|
| Completed | 2 | 40 | Europe | Ibrutinib Oral Capsule [Imbruvica], R-CHOEP chemotherapy | University Hospital Muenster, Janssen-Cilag G.m.b.H | Diffuse Large B Cell Lymphoma | 12/23 | 12/23 | | |
| Schliemann, Christoph |
| Recruiting | 3 | 102 | Europe | Onfekafusp alfa, L19TNF, Doxorubicin | Philogen S.p.A. | Soft Tissue Sarcoma | 12/25 | 12/25 | | |
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
| Active, not recruiting | 2 | 98 | Europe | Dacarbazine, DTIC, onfekafusp alfa, L19TNF | Philogen S.p.A., Philogen S.p.A., | Soft Tissue Sarcoma | 12/25 | 12/25 | | |
| Recruiting | 2 | 146 | Europe | Venetoclax plus Azacitidine, standard of care chemotherapy plus gemtuzumab ozogamicin | Technische Universität Dresden, University Hospital Heidelberg, AbbVie | Acute Myeloid Leukemia | 09/28 | 09/28 | | |
| Active, not recruiting | 1/2 | 55 | Europe | Venetoclax Oral Tablet, Cytarabin | Technische Universität Dresden, AbbVie | Relapsed Adult AML, Refractory AML | 10/23 | 08/25 | | |
| Recruiting | 1/2 | 214 | Europe | MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, Rydapt, Mylotarg, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO, MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin, MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin | Technische Universität Dresden, Novartis Pharmaceuticals, Pfizer | Acute Myeloid Leukemia | 04/27 | 04/28 | | |
| Zarbock, Alexander |
AKITA, NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery |
|
|
| Terminated | 2 | 177 | Europe, Canada, US, RoW | RMC-035, ROSgard, Placebo | Guard Therapeutics AB | Acute Kidney Injury | 04/23 | 07/23 | | |
MODIFYCSX, NCT06279793: Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients |
|
|
| Recruiting | 2 | 120 | Europe | Long-chain n-3 fatty acids, Omegaven®, Intravenous 0.9% Sodium Chloride, Saline Infusion | GCP-Service International West GmbH, University Hospital, Bonn, University Hospital Muenster, University Hospital Goettingen, University Hospital Schleswig-Holstein, Charite University, Berlin, Germany, Wuerzburg University Hospital | Cardiac Surgery, High Risk Patients, Intensive Care Unit, Cardiopulmonary Bypass, Valve Surgeries | 12/24 | 12/25 | | |
| Recruiting | 2 | 66 | Europe, US | Reparixin 600mg, REP, Matching Placebo, Control | Dompé Farmaceutici S.p.A, Dompè farmaceutici s.p.a. | Acute Respiratory Distress Syndrome, Adult | 08/25 | 08/25 | | |
NCT03567577 / 2017-003855-47: Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS |
|
|
| Recruiting | 2 | 95 | Europe | Solnatide 25 mg powder for reconstitution for solution for inhalation, AP301, 0.9% Saline Solution | Apeptico Forschung und Entwicklung GmbH | ARDS | 12/24 | 12/24 | | |
POINTER, NCT06475274: A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery |
|
|
| Recruiting | 2 | 161 | Europe, Canada | RMC-035, Placebo | Guard Therapeutics AB | Kidney Injury Following Open-Chest Cardiac Surgery | 10/25 | 10/25 | | |
| Recruiting | N/A | 600 | Europe, RoW | Critically ill patients with continuous renal replacement therapy | University Hospital Muenster, Baxter Healthcare Corporation | Critically Ill, Continuous Renal Replacement Therapy, Infections | 05/25 | 08/25 | | |
| Lenz, Georg |
COPA-R-CHOP, NCT04263584: Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL |
|
|
| Active, not recruiting | 2 | 62 | Europe | Copanlisib, R-CHOP Chemotherapy | University Hospital Muenster, Bayer | Diffuse Large B Cell Lymphoma | 04/25 | 04/25 | | |
| Claus, Inga |
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
|
|
| Completed | 3 | 523 | Europe, US | buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo | Annovis Bio Inc., TFS Trial Form Support | Parkinson's Disease, Idiopathic | 12/23 | 12/23 | | |
| Completed | 3 | 507 | Europe, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 01/24 | 02/24 | | |
| Completed | 3 | 522 | Europe, Canada, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 06/24 | 06/24 | | |
| Active, not recruiting | 2 | 159 | Europe, Japan, US | TAK-341, MEDI1341, Placebo | Takeda, AstraZeneca | Multiple System Atrophy | 07/25 | 07/25 | | |
| Trebicka, Jonel |
| Completed | 3 | 410 | Europe, Canada, US, RoW | Albutein 20% Injectable Solution, Standard medical treatment | Grifols Therapeutics LLC, Instituto Grifols, S.A. | Decompensated Cirrhosis and Ascites | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 238 | Europe, Canada, Japan, US, RoW | Linerixibat, Placebo | GlaxoSmithKline | Pruritus | 10/24 | 01/25 | | |
| Recruiting | 3 | 380 | Europe, US | SMT + PE-A 5%, Albutein 5%, Standard Medical Treatment, SMT | Grifols Therapeutics LLC, Instituto Grifols, S.A. | Acute-On-Chronic Liver Failure | 10/26 | 10/26 | | |
| Recruiting | 3 | 251 | Europe, Canada, Japan, US, RoW | Linerixibat | GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited | Cholestasis | 02/27 | 02/27 | | |
| Recruiting | N/A | 196 | Europe | Transjugular intrahepatic portosystemic shunt, TIPS | W.L.Gore & Associates | Chronic Liver Disease | 01/25 | 01/28 | | |
| Steinbicker, Andrea |
| Recruiting | N/A | 100 | Europe | | Goethe University, Pharmacosmos A/S, University Hospital Muenster | Anemia, IV Iron | 12/23 | 12/23 | | |
| Zarbock |
AKITA, NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery |
|
|
| Terminated | 2 | 177 | Europe, Canada, US, RoW | RMC-035, ROSgard, Placebo | Guard Therapeutics AB | Acute Kidney Injury | 04/23 | 07/23 | | |
| Recruiting | N/A | 600 | Europe, RoW | Critically ill patients with continuous renal replacement therapy | University Hospital Muenster, Baxter Healthcare Corporation | Critically Ill, Continuous Renal Replacement Therapy, Infections | 05/25 | 08/25 | | |
| Completed | N/A | 1180 | Europe | Comprehensive Implementation of the Bundle recommended by the "Kidney Disease: Improving Global Outcomes Group" (KDIGO bundle) | University Hospital Muenster, BioMérieux | Acute Kidney Injury | 06/24 | 09/24 | | |
PrevProgAKI, NCT05275218: Effect of an Intervention to Prevent Acute Kidney Injury Versus Standard Care in High-risk Patients After Major Surgery |
|
|
| Recruiting | N/A | 480 | Europe | Implementation of the KDIGO bundle) | University Hospital Muenster, Baxter Healthcare Corporation | Acute Kidney Injury (Nontraumatic) | 09/25 | 12/25 | | |
| Meersch, Melanie |
| Terminated | 3 | 440 | Europe | Albutein® 200 g/L or Plasbumin® 20, Human Albumin 20% | Jena University Hospital, German Research Foundation, Instituto Grifols, S.A., University Hospital Goettingen, SepNet - Critical Care Trials Group, Center for Sepsis Control and Care, Germany | Septic Shock | 07/22 | 06/23 | | |
| Schwake, Anna-Lena |
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
|
|
| Completed | 3 | 523 | Europe, US | buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo | Annovis Bio Inc., TFS Trial Form Support | Parkinson's Disease, Idiopathic | 12/23 | 12/23 | | |
| Piekarski, Florian |
MODIFYCSX, NCT06279793: Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients |
|
|
| Recruiting | 2 | 120 | Europe | Long-chain n-3 fatty acids, Omegaven®, Intravenous 0.9% Sodium Chloride, Saline Infusion | GCP-Service International West GmbH, University Hospital, Bonn, University Hospital Muenster, University Hospital Goettingen, University Hospital Schleswig-Holstein, Charite University, Berlin, Germany, Wuerzburg University Hospital | Cardiac Surgery, High Risk Patients, Intensive Care Unit, Cardiopulmonary Bypass, Valve Surgeries | 12/24 | 12/25 | | |
| Wempe, Carola |
MODIFYCSX, NCT06279793: Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients |
|
|
| Recruiting | 2 | 120 | Europe | Long-chain n-3 fatty acids, Omegaven®, Intravenous 0.9% Sodium Chloride, Saline Infusion | GCP-Service International West GmbH, University Hospital, Bonn, University Hospital Muenster, University Hospital Goettingen, University Hospital Schleswig-Holstein, Charite University, Berlin, Germany, Wuerzburg University Hospital | Cardiac Surgery, High Risk Patients, Intensive Care Unit, Cardiopulmonary Bypass, Valve Surgeries | 12/24 | 12/25 | | |
| Schwab, Nicholas |
| No trials found |
| Klaas, Christoph |
| No trials found |
